What Bioventus Inc. told the SEC could break it.

Bioventus is highly dependent on a limited number of products for revenue and profitability: its HA products alone accounted for approximately 49% of total revenue in 2025 (up from 46% and 43% in 2024 and 2023), so any setback specific to the HA franchise — competitive, clinical, reimbursement, supply (single-source manufacturers) or regulatory — would have an outsized adverse effect on its overall revenue and margins.

“We are highly dependent on a limited number of products for revenue generation and profitability. Our HA products accounted for 49%, 46% and 43% of our total revenue for the years ended Decemb”

Bioventus depends on a limited number of suppliers and single-source third-party manufacturers: its top three single-source third-party manufacturers supply its hyaluronic-acid (HA) products and constituted 49% of total net sales in 2025 (46%/43% in 2024/2023), and third-party manufacturers (primarily in Japan, Switzerland, Sweden and the U.S.) also make its EXOGEN, certain Surgical Solutions, PNS and PRP products; because few suppliers operate under FDA QSR requirements with the needed expertise/capacity, a disruption, capacity shortfall, contamination or loss of one of these single-source manufacturers could cause supply shortages and materially harm its business.

“Our top three single-source third-party manufacturers supply us with our HA products and constituted 49%, 46% and 43% of total net sales for the years ended December 31, 2025, 2024 and 2023”

Bioventus has customer-concentration and related credit risk: one customer accounted for product sales of $64.5 million, or 11.4% of total net sales, in 2025 (10.4% in 2024), and one customer represented approximately 28.1% of its accounts-receivable balance at December 31, 2025; loss of, reduced purchasing by, or a payment default from this large (undisclosed) customer would materially affect its revenue and could create a concentrated credit loss.

“The Company had product sales to one customer totaling $ 64,521 and $ 59,742 , primarily in the U.S. reporting segment representing 11.4 % and 10.4 % of total net sales during the years ended December 31, 2025 and 2024, respectively.”

Bioventus is exposed to FDA medical-device regulation (it is an FDA-registered manufacturer subject to QSR/cGMP and facility inspections, with potential product reclassification) and to third-party reimbursement: CMS implemented a 2.8% reduction in the RVU conversion factor in 2025 plus a 1% surgery RVU cut (which reduce surgeons' professional fees and may shift device choice), is changing DMEPOS payment mechanisms, and broader healthcare reform or reimbursement reductions could lower demand; it is also exposed to new/retaliatory import tariffs on goods from the EU, Switzerland, Canada, Mexico, Japan and China that raise its costs.

“CMS implemented a 2.8% reduction in the relative value unit (“RVU”) conversion factor in 2025, in addition to a 1% specific cut in surgery RVUs. While such reductions do not directly lower the prices of our devices, they reduce the professional services fee received by the surgeon, and may impact such surgeon's choice of devices.”